From collaboration to innovation: How multidisciplinary teams and clinical trials are transforming melanoma care

In this episode from MIA’s podcast Melanoma Insights for Professionals, our experts explore the critical role of multidisciplinary collaboration in delivering contemporary melanoma care. Hear how melanoma multidisciplinary teams (MDTs) bring together diverse expertise to navigate increasingly complex treatment pathways, discuss challenging cases and identify opportunities for patients to participate in clinical trials.

The discussion provides insight into how MDTs operate in practice, the value they bring to patient outcomes, and how collaboration between clinicians and researchers continues to drive progress.

The panel also explores why clinical trials remain fundamental to advancing melanoma care, how practice-changing evidence has shaped current standards of treatment, and what emerging developments may define the future of melanoma management.

This podcast is suitable for multidisciplinary specialists, clinical trial researchers and other healthcare professionals.

REFERENCE

• GV Long, et al. A phase 2 study of neoadjuvant nivolumab (nivo) + relatlimab (rela) in high-risk stage II cutaneous melanoma (NeoReNi). J Clin Oncol 44, 9502-9502(2026).

SPEAKERS

• Prof Alexander van Akkooi - Surgical Oncologist | Melanoma Institute Australia and The University of Sydney

• Prof Georgina Long AO - Medical Oncologist and Medical Director | Melanoma Institute Australia, The University of Sydney and Royal North Shore Hospital

• Maria Gonzalez - CEO and former Head of Clinical Trials | Melanoma Institute Australia

Please note that this podcast was accurate at the time of recording (June 2026) but may not reflect the rapidly evolving treatment landscape and approvals in Australia.

Melanoma Institute Australia’s Education Program⁠ is proudly supported through unrestricted educational grants from BMS, MSD and HEINE.